| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. | President | Common Stock | 139K | $233K | $1.67 | Feb 18, 2025 | Indirect |
| Neumora Therapeutics, Inc. | President | Common Stock | 77K | $129K | $1.67 | Feb 18, 2025 | Direct |
| Neumora Therapeutics, Inc. | President | Stock Option (Right to Buy) | 170K | Feb 13, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| NMRA | Neumora Therapeutics, Inc. | Feb 18, 2025 | 1 | -$13.5K | 4 | Feb 20, 2025 | President |
| NMRA | Neumora Therapeutics, Inc. | Feb 13, 2025 | 13 | $0 | 4 | Feb 18, 2025 | President |
| MTSR | Metsera, Inc. | Jan 30, 2025 | 0 | $0 | 3 | Jan 30, 2025 | Director |
| NMRA | Neumora Therapeutics, Inc. | Aug 27, 2024 | 1 | -$179K | 4 | Aug 27, 2024 | Chief Financial Officer |
| NMRA | Neumora Therapeutics, Inc. | Aug 22, 2024 | 3 | -$984K | 4 | Aug 26, 2024 | Chief Financial Officer |
| NMRA | Neumora Therapeutics, Inc. | Apr 17, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Chief Financial Officer |
| NMRA | Neumora Therapeutics, Inc. | Feb 14, 2024 | 2 | $0 | 4 | Feb 16, 2024 | Chief Financial Officer |
| NMRA | Neumora Therapeutics, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | Chief Financial Officer |